No such thing as a free expert, GAO tells FDA in heparin conflict of interest case
This article was originally published in Scrip
A new code of conduct introduced by the US FDA after extended criticism of the agency's response to the 2008 heparin crisis will alter the way the FDA interacts with industry personnel who volunteer help and advice to deal with "emergencies" such as suspected drug contaminations. A Government Accountability Office (GOA) report released last month claims that the FDA did not recognise or did not respond properly to the potential conflicts of interests that arose from its working with industry-associated personnel. The GOA recommended that the FDA needed to tighten its paper trail under such circumstances, and the agency responded by amending its staff guidance notes with a section on "External Expert Gratuitous Services in an Emergency".
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.